History of the NEJM & COI
“During the decade of the 1990s, when I was editor-in-chief of the New England Journal of Medicine, we rejected anyone who had a conflict of interest from writing an editorial or review article. Sometimes it required going down the list until we found someone who didn't have a conflict, but we never had to compromise and accept someone without sufficient expertise to do a good job. I also think it's often a good idea to get someone who isn't too close to the action: it often avoids “group think” and provides a fresh perspective. But to maintain our 1990s policy takes more work because you can't just accept the first person who pops into your mind. I was disappointed when the journal changed the policy, and said so publicly.”
– Kassirer JP, British Medical Journal 2001
Current media campaign in the NEJM
Industry funding of NEJM
Conflicted nature of medical publishing
Managing COI: Who should write review articles and guidelines?
Is there a shortage of authors for review articles?
- No, Phramascolds are not worse than the pervasive conflicts of interest they criticize: Larry Husten in Forbes
- Medical journals are an extension of the marketing arm of pharmaceutical companies. Smith R, PLOS Medicine 2005.
Addendum 6/3/2015: Drs. Kassirer and Angell (prior editors of the NEJM referenced above) just published an editorial in the BMJ here. It is a must-read.
- IBCC chapter – Disseminated Intravascular Coagulation (DIC) - January 18, 2021
- PulmCrit- RCTs don't justify using convalescent plasma or antibody cocktails - January 14, 2021
- PulmCrit – Six RCTs to answer one question: what is the role of tocilizumab in COVID-19? - January 12, 2021